Abstract:Background. Several studies have demonstrated that acetylation was involved in the process of liver cancer. This study aimed to establish an effective predictive prognostic model using acetylation regulation genes in liver cancer. Methods. Two datasets were downloaded from the Cancer Genome Atlas (TCGA) database and International Cancer Genome Consortium (ICGC) database. Differentially expressed acetylation regulation genes were identified in the TCGA-LIHC dataset, and then, Gene Ontology (GO) functional annotation analysis was used to investigate the molecular mechanism. After grouping the patients into clusters based on consensus clustering, we explored the correlation between clusters and clinical characteristics. A risk model was constructed by the least absolute shrinkage and selection operator (LASSO) regression analysis to calculate the risk score. Patients were divided into high-risk and low-risk groups according to the risk score using the acetylation regulation genes. Data downloaded from LIRI-JP were used for external validation. Univariate and multivariate Cox regressions were performed to identify independent risk factors. A prognostic nomogram was constructed according to the TCGA-LIHC dataset. The effect of HDAC11 expression on the proliferation and migration of liver cancer was detected by the CCK-8 method and cell scratch test, respectively. Results. Eleven of 29 acetylation regulation genes were identified as upregulated differentially expressed genes. Go enrichment analysis showed that they were involved in "protein and histone deacylation and deacetylation." Patients were categorized into two clusters according to the expression of 29 acetylation regulation genes. Compared with cluster 2, cluster 1 correlated with shorter overall survival (OS) and higher expression. Stage, T stage, grade, gender, age, and follow-up state were significantly different between two clusters. Pathways involved in DNA repair were significantly enriched in cluster 1. The risk score was calculated by HDAC1, HDAC2, HDAC4, HDAC11, HAT1, and SIRT6. Patients in the high-risk group had a worse prognosis in both datasets. Risk score was not only an independent prognostic marker but could also predict the clinicopathological features of liver cancer. A nomogram containing risk score, T stage, and M stage was built to predict overall survival. After transfection with HDAC11 overexpression plasmid, the proliferation ability of HepG2 cells increased, while the migration ability had no change. Conclusions. Our findings suggested that acetylation regulation genes contribute to malignant progression and have a clinical prognostic impact on liver cancer.

Disturbed mitochondrial acetylation in accordance with the availability of acetyl groups in hepatocellular carcinoma

Acetyl-CoA Regulates Lipid Metabolism and Histone Acetylation Modification in Cancer

Impact of Acetylation on Tumor Metabolism

Profiles of Acetylation Regulation Genes Contribute to Malignant Progression and Have a Clinical Prognostic Impact on Liver Cancer

ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition.

Acetylation Control Of Cancer Cell Metabolism

Lysine Acetylome Study Of Human Hepatocellular Carcinoma Tissues For Biomarkers And Therapeutic Targets Discovery

Suppression of Alpha-Tubulin Acetylation Potentiates Therapeutic Efficacy of Eribulin in Liver Cancer.

In-depth Profiling and Quantification of the Lysine Acetylome in Hepatocellular Carcinoma with a Trapped Ion Mobility Mass Spectrometer

Acetate Functions As an Epigenetic Metabolite to Promote Lipid Synthesis under Hypoxia.

A glimpse into novel acylations and their emerging role in regulating cancer metastasis

Acetyl-CoA Metabolism As a Therapeutic Target for Cancer

Acetylation Control of Metabolic Enzymes in Cancer: an Updated Version

Tetrameric Acetyl-CoA Acetyltransferase 1 is Important for Tumor Growth.

Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects

PDHX acetylation facilitates tumor progression by disrupting PDC assembly and activating lactylation mediated gene expression

Acetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer

The role of protein acetylation in carcinogenesis and targeted drug discovery

Targeting the acetylation signaling pathway in cancer therapy

Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification

Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B‐related hepatocellular carcinoma